[{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"LaNova Medicines","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"Intravenous Injection","sponsorNew":"LaNova Medicines \/ LaNova Medicines","highestDevelopmentStatusID":"10","companyTruncated":"LaNova Medicines \/ LaNova Medicines"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LM-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"8","companyTruncated":"LaNova Medicines \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"LM-305","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"LaNova Medicines \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ AstraZeneca"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LM-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LM-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LM-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LM101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LM-24C5","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LM-2417","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LM-168","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LM-061","moa":"c-Met","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LM-061","moa":"c-Met","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Asymchem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LaNova Medicines \/ LaNova Medicines","highestDevelopmentStatusID":"1","companyTruncated":"LaNova Medicines \/ LaNova Medicines"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"GI Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"GI-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LaNova Medicines \/ LaNova Medicines","highestDevelopmentStatusID":"4","companyTruncated":"LaNova Medicines \/ LaNova Medicines"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Apatinib","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"LaNova Medicines","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LaNova Medicines \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LM302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Shanghai Zhongshan Hospital | First Affiliated Hospital of Harbin Medical University | First Affiliated Hospital of Zhejiang University | Sir Run Run Shaw Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LM-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Shanghai Zhongshan Hospital | First Affiliated Hospital of Harbin Medical University | First Affiliated Hospital of Zhejiang University | Sir Run Run Shaw Hospital","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Shanghai Zhongshan Hospital | First Affiliated Hospital of Harbin Medical University | First Affiliated Hospital of Zhejiang University | Sir Run Run Shaw Hospital"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LM-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"LaNova Medicines","amount2":0.22,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Turning Point Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"LaNova Medicines \/ Turning Point Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by LaNova Medicines
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
